|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
Datamonitor, Aug 2010, Pages: 125
Introduction
Expanding healthcare coverage in emerging Asia-Pacific markets, rapid economic growth and burgeoning middle classes are attracting foreign M&A as companies attempt to offset future losses from the looming threat of the 2011 “patent cliff” and slowing growth in major developed markets. As these markets develop, consolidation of the domestic industry is also driving M&A in the Asia-Pacific region.
Scope
-Provides an overview of the healthcare systems and pharmaceutical markets of key countries within Asia-Pacific.
-Overview of drivers, resistors and trends within the Asia-Pacific M&A landscape.
-Analysis of the types of acquisitions and healthcare sectors targeted.
-Analysis of geographic M&A activity and transaction values.
Highlights
Sluggish performance in the major pharmaceutical markets prompted by growing generic competition and increasing healthcare cost-containment are forcing companies to seek opportunities elsewhere. Massive populations, rapid economic growth and burgeoning middle classes make emerging Asia-Pacific markets particularly attractive to foreign companies.
Companies penetrating these markets often acquire local manufacturers and generics firms that provide a quick, cost-effective point of entry from which to later launch more expensive branded products. However, some Asia-Pacific countries are introducing or considering measures to protect the domestic industries from foreign domination.
Within the period analyzed in this report, the highest number of M&A deals involving APAC based companies was recorded in 2008. Strong recovery from the global financial crisis can be seen in late 2009. Furthermore, 2010 seems to be off to a good start, with a number of large deals involving APAC-based companies having been announced.
Reasons to Purchase
-Gain insight into the number and scope of M&A transactions in Asia-Pacific, and key drivers and resistors.
-Identify which are the most perused pharmaceutical sectors in terms of M&A deals, and which companies have been the most acquisitive in recent years.
-Identify which markets have been most frequently targeted through M&As, and which have attracted the attention of Big Pharma.
Customers who bought this item also bought
Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity
Pharmaceutical M&A in the Asia Pacific Region
Seasonal Influenza Vaccine Market in Asia - Pacific Region - Threat of Pandemic Influenza and Increasing Vaccination Coverage to Drive Growth
Pharmaceutical Licensing and Alliances in the Asia-Pacific Region - Pharma enhances its focus on APAC markets
Healthcare System and Delivery Network - 2010 Yearbook
Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force
Healthcare Reform in China
Pharmaceuticals - Global Outlook
Emerging Pharmaceutical Market in China - Forecast to Become The World’s Third-Largest Pharmaceutical Market By 2013
Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates
|
|
|
|
